103 related articles for article (PubMed ID: 23077137)
1. The effects of simvastatin on the pharmacokinectics of sitagliptin.
Cerra M; Luo WL; Li SX; Matthews C; O'Neill EA; Wagner JA; Stoch SA; Anderson MS
J Popul Ther Clin Pharmacol; 2012; 19(3):e356-60. PubMed ID: 23077137
[TBL] [Abstract][Full Text] [Related]
2. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Steinberg H; Anderson MS; Musliner T; Hanson ME; Engel SS
Vasc Health Risk Manag; 2013; 9():273-82. PubMed ID: 23761972
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
4. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
5. Effect of sitagliptin on the pharmacokinetics of simvastatin.
Bergman AJ; Cote J; Maes A; Zhao JJ; Roadcap BA; Sun L; Valesky RJ; Yang A; Keymeulen B; Mathijs Z; De Smet M; Laethem T; Davies MJ; Wagner JA; Herman GA
J Clin Pharmacol; 2009 Apr; 49(4):483-8. PubMed ID: 19204138
[No Abstract] [Full Text] [Related]
6. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Ramadan WH; Kabbara WK
Vasc Health Risk Manag; 2015; 11():125-32. PubMed ID: 25709467
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
[TBL] [Abstract][Full Text] [Related]
10. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):745-58. PubMed ID: 22587686
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
K P A; Meda VS; Kucherlapati VS; Dubala A; M D; P R AV; K E; B S
Eur J Clin Pharmacol; 2012 May; 68(5):709-14. PubMed ID: 22173280
[TBL] [Abstract][Full Text] [Related]
13. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Krishna R; Bergman A; Larson P; Cote J; Lasseter K; Dilzer S; Wang A; Zeng W; Chen L; Wagner J; Herman G
J Clin Pharmacol; 2007 Feb; 47(2):165-74. PubMed ID: 17244767
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin and simvastatin (juvisync).
Med Lett Drugs Ther; 2011 Nov; 53(1377):89. PubMed ID: 22075668
[No Abstract] [Full Text] [Related]
17. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
19. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.
Kao DP; Kohrt HE; Kugler J
Diabet Med; 2008 Oct; 25(10):1229-30. PubMed ID: 19046202
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
